I Teos Therapeutics, Inc. ITOS
We take great care to ensure that the data presented and summarized in this overview for iTeos Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITOS
View all-
Black Rock Inc. New York, NY3.73MShares$24.3 Million0.0% of portfolio
-
Mpm Asset Management LLC Cambridge, MA2.74MShares$17.8 Million16.91% of portfolio
-
Bvf Inc San Francisco, CA2.33MShares$15.1 Million0.67% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.09MShares$13.6 Million0.26% of portfolio
-
Jpmorgan Chase & CO New York, NY2.07MShares$13.5 Million0.0% of portfolio
-
Bio Impact Capital LLC Cambridge, MA1.75MShares$11.4 Million2.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$10.6 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.43MShares$9.32 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.21MShares$7.88 Million0.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ922KShares$6 Million0.03% of portfolio
Latest Institutional Activity in ITOS
Top Purchases
Top Sells
About ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Insider Transactions at ITOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 07
2025
|
Matthew Call Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+12.91%
|
-
|
|
Mar 07
2025
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,300
+24.84%
|
-
|
|
Mar 07
2025
|
Matthew Gall Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+21.16%
|
-
|
|
Mar 07
2025
|
Michel Detheux Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
77,000
+36.17%
|
-
|
|
Dec 06
2024
|
David Feltquate Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,000
+50.0%
|
-
|
|
Nov 19
2024
|
Matthew Gall Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+7.1%
|
$35,000
$7.73 P/Share
|
|
May 12
2024
|
Ra Capital Management, L.P. |
SELL
Other acquisition or disposition
|
Indirect |
900,000
-26.12%
|
-
|
|
May 10
2024
|
Boxer Capital, LLC |
BUY
Grant, award, or other acquisition
|
Direct |
1,142,857
+27.94%
|
$19,428,569
$17.5 P/Share
|
|
Dec 05
2023
|
Michel Detheux Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+33.74%
|
-
|
|
Dec 05
2023
|
Matthew Gall Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+40.42%
|
-
|
|
Dec 05
2023
|
Matthew Call Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+24.19%
|
-
|
|
Dec 05
2023
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,000
+50.0%
|
-
|
|
Oct 12
2023
|
Matthew Gall Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+20.47%
|
$40,000
$8.37 P/Share
|
|
Aug 23
2023
|
Boxer Capital, LLC |
SELL
Open market or private sale
|
Direct |
350,000
-5.66%
|
$5,250,000
$15.56 P/Share
|
|
Mar 28
2023
|
Matthew Call Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,226
+29.99%
|
$80,452
$2.95 P/Share
|
|
Jun 09
2022
|
David Hallal |
SELL
Open market or private sale
|
Direct |
1,171
-100.0%
|
$22,249
$19.51 P/Share
|
|
Jun 09
2022
|
David Hallal |
BUY
Exercise of conversion of derivative security
|
Direct |
1,171
+50.0%
|
$4,684
$4.23 P/Share
|
|
Jun 08
2022
|
David Hallal |
SELL
Open market or private sale
|
Direct |
28,444
-100.0%
|
$568,880
$20.21 P/Share
|
|
Jun 08
2022
|
David Hallal |
BUY
Exercise of conversion of derivative security
|
Direct |
28,444
+50.0%
|
$85,332
$3.8 P/Share
|
|
May 11
2022
|
Aaron I. Davis |
SELL
Open market or private sale
|
Indirect |
338,000
-6.78%
|
$5,746,000
$17.89 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.33M shares |
|---|---|
| Open market or private purchase | 5K shares |
| Other acquisition or disposition | 900K shares |
|---|